Zacks: Brokerages Anticipate Trevena Inc (TRVN) to Post -$0.09 Earnings Per Share

Analysts forecast that Trevena Inc (NASDAQ:TRVN) will announce earnings of ($0.09) per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Trevena’s earnings. Trevena reported earnings per share of ($0.13) in the same quarter last year, which suggests a positive year-over-year growth rate of 30.8%. The business is scheduled to announce its next quarterly earnings results on Thursday, August 1st.

On average, analysts expect that Trevena will report full year earnings of ($0.37) per share for the current year. For the next fiscal year, analysts forecast that the company will report earnings of ($0.23) per share. Zacks’ EPS averages are a mean average based on a survey of research firms that cover Trevena.

Trevena (NASDAQ:TRVN) last announced its quarterly earnings data on Friday, May 10th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.08) by $0.02.

Several research firms have commented on TRVN. Zacks Investment Research raised shares of Trevena from a “hold” rating to a “buy” rating and set a $1.50 target price for the company in a research report on Thursday, February 7th. HC Wainwright reissued a “hold” rating and issued a $1.25 target price on shares of Trevena in a research report on Thursday, March 14th. Finally, ValuEngine downgraded shares of Trevena from a “hold” rating to a “sell” rating in a research report on Friday, May 3rd. One investment analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the company’s stock. Trevena presently has an average rating of “Hold” and an average price target of $4.69.

TRVN traded up $0.01 on Friday, reaching $1.35. 612,876 shares of the company traded hands, compared to its average volume of 984,596. Trevena has a 52-week low of $0.38 and a 52-week high of $3.58. The company has a market capitalization of $124.68 million, a PE ratio of -3.21 and a beta of 2.55. The company has a debt-to-equity ratio of 0.18, a quick ratio of 3.55 and a current ratio of 3.58.

A number of hedge funds have recently bought and sold shares of the business. Vanguard Group Inc grew its position in Trevena by 29.2% in the third quarter. Vanguard Group Inc now owns 2,618,634 shares of the biopharmaceutical company’s stock worth $5,552,000 after acquiring an additional 592,152 shares in the last quarter. Vanguard Group Inc. grew its position in Trevena by 29.2% in the third quarter. Vanguard Group Inc. now owns 2,618,634 shares of the biopharmaceutical company’s stock worth $5,552,000 after acquiring an additional 592,152 shares in the last quarter. BlackRock Inc. grew its position in Trevena by 38.8% in the first quarter. BlackRock Inc. now owns 2,597,930 shares of the biopharmaceutical company’s stock worth $4,052,000 after acquiring an additional 725,717 shares in the last quarter. Renaissance Technologies LLC grew its position in Trevena by 84.2% in the first quarter. Renaissance Technologies LLC now owns 1,284,038 shares of the biopharmaceutical company’s stock worth $2,003,000 after acquiring an additional 587,100 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in Trevena by 17.5% in the third quarter. JPMorgan Chase & Co. now owns 541,099 shares of the biopharmaceutical company’s stock worth $1,147,000 after acquiring an additional 80,437 shares in the last quarter. 21.54% of the stock is owned by institutional investors.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of treatment options that target and treat diseases affecting the central nervous system. Its product candidates include Oliceridine injection, a G protein biased mu-opioid receptor (MOR) ligand that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is warranted; TRV250, a G protein biased delta- opioid receptor ligand, which is in Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; TRV027 for the treatment of acute heart failure; and TRV045, a novel S1P modulator for managing chronic pain.

See Also: Compound Annual Growth Rate (CAGR)

Get a free copy of the Zacks research report on Trevena (TRVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Trevena (NASDAQ:TRVN)

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.